Divi’s Laboratories: Divi’s Labs won big in a low-value segment with a curated portfolio. Will its dream run sustain?

Drug maker Divi’s Laboratories has come to acquire a distinct edge that its peers envy. It has won the trust of customers and guarded itself relatively better against headwinds. Investors continue to believe in Divi’s, a deep bond they have shared since its listing in 2003. For months now, Divi’s has been sitting firmly atop the market capitalisation in its industry group, second only to Sun Pharmaceutical Industries. On July 20, Divi’s market